Approximately 40 percent of adults with chronic pain experience depression or anxiety, according to a review published ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

Migraine disrupts daily life with invisible neurological pain, causing physical, emotional, and cognitive struggles that go ...

The one-size-fits-all approach to pain management should be a thing of the past. But we’re still not there yet.

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

Zavegepant nasal spray yielded sustained relief of acute pain and function in migraine and may benefit patients for whom triptans are inappropriate. Compared with placebo, zavegepant provides ...

Older age, increasing medical complexity, specific psychiatric disorder were associated with prolonged boarding. (HealthDay News) — Boarding for pediatric mental health (MH) conditions while ...